PolyPeptide Group AG (LTS:0AAJ) Total Liabilities: CHF469.2 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0AAJ PolyPeptide Group AG LTS:0AAJ
57 GF Score
Price CHF43.98
GF Value CHF34.96
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is PolyPeptide Group AG Total Liabilities?

PolyPeptide Group AG LTS:0AAJ -0.06% 57 Total Liabilities is CHF469.2 Mil as of Jun. 2026. GuruFocus rates LTS:0AAJ with a GF Score™ of 57/100 and a GF Value™ of CHF34.96 (Modestly Overvalued). The stock has 5 warning signs investors should review.

PolyPeptide Group AG's Total Liabilities for the quarter that ended in Jun. 2026 was CHF469.2 Mil.

PolyPeptide Group AG's quarterly Total Liabilities increased from Jun. 2025 (CHF414.65 Mil) to Dec. 2025 (CHF452.91 Mil) and increased from Dec. 2025 (CHF452.91 Mil) to Jun. 2026 (CHF469.23 Mil).

PolyPeptide Group AG's annual Total Liabilities increased from Dec. 2023 (CHF290.34 Mil) to Dec. 2024 (CHF372.82 Mil) and increased from Dec. 2024 (CHF372.82 Mil) to Dec. 2025 (CHF452.91 Mil).

PolyPeptide Group AG Total Liabilities Historical Data

* Premium members only.

The historical data trend for PolyPeptide Group AG's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PolyPeptide Group AG Total Liabilities Chart

PolyPeptide Group AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 180.94 152.08 290.34 372.82 452.91

PolyPeptide Group AG Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 293.50 372.82 414.65 452.91 469.23
LTS:0AAJ
57GF Score
PolyPeptide Group AG LTS:0AAJ
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PolyPeptide Group AG Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

PolyPeptide Group AG's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=174.061+(116.654+134.341
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+27.853+0)
=452.9

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=770.734-317.825
=452.9

PolyPeptide Group AG's Total Liabilities for the quarter that ended in Jun. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=195.308+(104.928+142.056
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+26.936+0)
=469.2

Total Liabilities=Total Assets (Q: Jun. 2026 )-Total Equity (Q: Jun. 2026 )
=792.644-323.416
=469.2

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of CHF469.2 Mil mean?
PolyPeptide Group AG (LTS:0AAJ) has a Total Liabilities of CHF469.2 Mil as of Jun. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PolyPeptide Group AG and its competitors.
Is PolyPeptide Group AG's Total Liabilities too high?
PolyPeptide Group AG's current Total Liabilities is CHF469.2 Mil. Overall, PolyPeptide Group AG has a GF Score™ of 57/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PolyPeptide Group AG's Total Liabilities compare to ZTS and UTHR?
PolyPeptide Group AG's Total Liabilities of CHF469.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for PolyPeptide Group AG and its competitors. PolyPeptide Group AG's current Total Liabilities is CHF469.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PolyPeptide Group AG stock overvalued right now?
Based on GuruFocus' analysis, PolyPeptide Group AG (LTS:0AAJ) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF34.96, compared to a current price of CHF43.98 — trading 25.8% above its estimated fair value. The current Total Liabilities is CHF469.2 Mil. PolyPeptide Group AG's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For PolyPeptide Group AG (LTS:0AAJ), the current Total Liabilities is CHF469.2 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is PolyPeptide Group AG (LTS:0AAJ) Overvalued in 2026?

Based on GuruFocus' analysis, PolyPeptide Group AG stock appears to be overvalued. The current stock price of CHF43.98 is trading 25.8% above its estimated GF Value™ of CHF34.96. GuruFocus considers PolyPeptide Group AG to be Modestly Overvalued.

Key valuation signals for LTS:0AAJ:

  • Total Liabilities: CHF469.2 Mil
  • GF Value™: CHF34.96 vs. price of CHF43.98 (25.8% above fair value)
  • GF Score™: 57/100 with 5 warning signs

No single metric tells the full story. See the LTS:0AAJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

PolyPeptide Group AG Business Description

Address Neuhofstrasse 24, Baar, Zug, CHE, 6340
PolyPeptide Group AG is an independent contract development and manufacturing organization (CDMO) focused on peptides and oligonucleotides employed as an active pharmaceutical ingredients (APIs) and used as intermediates in therapeutic products. The company derives majority of its revenue from Europe and Asia.
57GF Score

Get the complete analysis for LTS:0AAJ

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF43.98
Price
CHF34.96
GF Value